CCHT is committed to growing into an open and
professional international enterprise.
Changchun High-tech Industry (Group) Co., Ltd. was established by Changchun High-tech Industry Development Corporation in June 1993, with a total share capital of 137,500,000 shares.
On December 18, 1996, CCHT stocks were listed at Shenzhen Stock Exchange. It is among the first batch of listed companies in northeast China.
Since its establishment more than 20 years ago, CCHT successfully transformed from high-tech area infrastructure construction into an enterprise group focusing on the field of medical science and technology innovation and implementing industrial investment. CCHT has adhered to the corporate culture of ‘‘innovation, concentration, generosity and sharing’’, practicing the core values of creating value for customers, creating opportunities for employees, creating benefits for shareholders and taking responsibility for the society. It has established its industrial orientation with biopharmaceutical industry as the primary and real estate industry as the supplement, has formed the development platform for three industries including genetic engineering pharmaceuticals, biological vaccines and modern traditional Chinese medicine, has realized the vigorous development pattern of ‘‘four carriages’’ including GeneScience Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘‘GenSci’’, Changchun BCHT Biotechnology Co., Ltd. (hereinafter referred to as ‘‘BCHT’’, Jilin Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as ‘‘Huakang Pharmaceutical’’) and Changchun High-tech Real Estate Development Co., Ltd. (hereinafter referred to as ‘‘High-tech Real Estate’’ and has opened up a good situation of shared development and win-win cooperation. The company's operating performance continued to grow, since 2017 for the first time into the national pharmaceutical industry top 100 list ranked 73, the ranking steadily rose in five consecutive years, respectively, 56, 45, 37, 27, 23.
